Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2023 · 10-Q
Revenue$19.50M$19.50M+14.3% vs Q3 2022 Net Income-$959.00K-$959.00KN/M vs Q3 2022 EPS Diluted-$0.01-$0.01N/M vs Q3 2022 Gross Profit$11,969,000+17.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived$396,000N/M Margins · derivedGross margin61.4%+1.6 pt vs Q3 2022
Operating margin-5.9%+12.1 pt vs Q3 2022
Net margin-4.9%+0.9 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 8, 2023 · 39 d after period end